Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial (2022)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciac345
PubMed Identifier: 35543372
Publication URI: http://europepmc.org/abstract/MED/35543372
Type: Journal Article/Review
Parent Publication: Clinical Infectious Diseases
Issue: 12
ISSN: 1058-4838